Viral and non-viral vectors are crucial gene delivery vehicles for cell and gene therapies, yet they are difficult to manufacture to a scale that meets the growing demand. Across vector characterization, raw materials and supply chain, there are many limitations and obstacles to consider.
In April 2020, we conducted a survey of cell and gene therapy professionals all over the world, to find out what difficulties they were experiencing, and which areas were in the greatest need of innovation.
The final report provides insight into the biggest opportunities and challenges surrounding viral and non-viral vector manufacturing which are ready to be addressed.
- 59% of the participants are working with viral methods when considering viral gene therapy delivery.
- 61% of the respondents see encountering stability issues as the main hurdle when cryopreserving their vectors.
- Viral vectors used in production and plasmids were voted to be the most limiting when considering raw and starting materials used in viral vector manufacturing.